Artivion, Inc. $AORT Stock Position Lessened by Perceptive Advisors LLC

Perceptive Advisors LLC decreased its holdings in Artivion, Inc. (NYSE:AORT) by 14.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,722,290 shares of the company’s stock after selling 297,710 shares during the quarter. Artivion accounts for approximately 1.4% of Perceptive Advisors LLC’s holdings, making the stock its 23rd largest position. Perceptive Advisors LLC owned approximately 3.64% of Artivion worth $78,554,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of AORT. Summit Partners Public Asset Management LLC bought a new position in shares of Artivion in the fourth quarter worth $39,401,000. Champlain Investment Partners LLC bought a new position in shares of Artivion in the third quarter worth $17,912,000. Goldman Sachs Group Inc. grew its stake in shares of Artivion by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock worth $24,510,000 after purchasing an additional 317,518 shares in the last quarter. Two Sigma Investments LP grew its stake in shares of Artivion by 235.5% in the third quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock worth $18,906,000 after purchasing an additional 313,446 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Artivion by 8.3% in the third quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after purchasing an additional 232,424 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Andrew M. Green sold 44,001 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the transaction, the senior vice president owned 60,259 shares of the company’s stock, valued at $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

AORT has been the subject of several recent analyst reports. Needham & Company LLC decreased their price target on Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Citizens Jmp decreased their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus set a $45.00 price target on Artivion in a research note on Monday, June 1st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $36.00 target price on shares of Artivion in a research note on Tuesday. Finally, Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.17.

Artivion Trading Down 0.8%

Shares of AORT stock opened at $21.27 on Thursday. The stock has a 50-day simple moving average of $28.16 and a 200 day simple moving average of $36.44. Artivion, Inc. has a fifty-two week low of $19.16 and a fifty-two week high of $48.25. The stock has a market capitalization of $1.03 billion, a P/E ratio of 88.63 and a beta of 1.26. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.